15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Emergent Biosolutions Inc, 1 rate it Buy or better, 0 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 61% above the current $6.20. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $1.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Hold
Strong Buy00%
Buy150%
Hold00%
Sell150%
Strong Sell00%
Based on 2 analysts giving stock ratings to Emergent Biosolutions Inc.
As of Sep, 1 of 2 firms rate EBS a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
EBS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.11 – $-0.05 · 2 analysts · -82% YoY
Next period, 2 analysts expect Emergent Biosolutions Inc to earn $-0.08 a share (range $-0.11 – $-0.05), versus $-0.43 a year earlier. Full-year consensus is $0.36, growing to $1.05 the year after.
REVENUE · NEXT QUARTER
$143.7M
Range $126.0M – $153.0M · 2 analysts · -3% YoY
Revenue is expected to reach $143.7M (range $126.0M – $153.0M), -3.4% year-over-year. Full-year consensus is $657.1M, rising to $703.3M next year.
Top analysts covering Emergent Biosolutions Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EBS.
#1
Jessica Fye
JP Morgan · Rank #71
Sell
No targeton EBS
Overall win rate
53%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$10.00+61.3% to target
Overall win rate
36%
+ Follow
#3
RW
Robert Wasserman
Benchmark · Rank #336
Buy
$12.00+93.5% to target
Overall win rate
39%
+ Follow
#4
BF
Brandon Folkes
Rodman & Renshaw
Buy
$16.00+158.1% to target
Coverage
—
+ Follow
EBS stock forecast FAQ
What is EBS's average 12-month price target?+
The 1 analysts with a live target average $10.00 for Emergent Biosolutions Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is EBS stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 1 are Sell or Strong Sell.
How many Wall Street analysts cover EBS?+
2 analysts have an active rating on Emergent Biosolutions Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering EBS?+
Among analysts who currently cover EBS, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #71). Their current call is Sell.
What is Emergent Biosolutions Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.11 – $-0.05) across 2 analysts. Full-year EPS is projected at $0.36, rising to $1.05 the following year.
How much revenue is Emergent Biosolutions Inc expected to report next quarter?+
Consensus revenue is $143.7M (range $126.0M – $153.0M). Full-year revenue is projected at $657.1M, growing to $703.3M next year.
Have analysts been upgrading or downgrading EBS lately?+
As of Sep, 1 of 2 firms rate EBS a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EBS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
